|Articles|September 1, 2019
- Pharmaceutical Executive-09-01-2019
- Volume 39
- Issue 9
Pharmaceutical Executive, September 2019 Issue (PDF)
Click the title above to open the Pharmaceutical Executive September 2019 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 7 years ago
Pharm Exec's 18th Annual Industry Auditalmost 7 years ago
Product Development: The Optimizer’s Cursealmost 7 years ago
Setting Your Launch Pathalmost 7 years ago
Pre-launch Prep: The Modern Protocolalmost 7 years ago
The Murky Outlook for Generic Drugsalmost 7 years ago
Post-Launch Birthday: The Time to Refinealmost 7 years ago
Product Launch: Five Paths Forwardalmost 7 years ago
Once Upon a Brandabout 7 years ago
Country Report: Chinaabout 7 years ago
Other Products to WatchAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Novartis, Bristol Myers Pause Autoimmune CAR-T Trials Over Safety Concerns: Report
2
Pharmaceutical Executive Daily: Novartis and BMS Halt CAR-T Trials
3
Roundup: Alteogen Enters Option & License Agreement with Novartis, NewBiologix & Synastra Form BioTech Partnership, RedHill Acquires Commercialization Rights to Rebyota & Clenpiq
4
Redefining Medical Strategy in Obesity Through Real-World iNSIGHTS
5